For more than 20 years, Atuka has been providing preclinical services that expand the frontiers of Parkinson’s disease research, and helping to make new, life-changing therapeutics a reality.
Atuka provides its partners with the highest-quality studies and data, as interpreted by world-leading neuroscientists, to ensure results that are consistently predictive and translatable.
Atuka’s lead scientists are responsible for numerous breakthroughs that have helped shape the direction of research in the field over the past three decades. Collectively they have published more than 300 peer-reviewed, highly-cited papers, and individually possess h-indices ranging from 25 to 70.
therapeutics evaluated
candidates proceeding to clinical trial
peer-reviewed academic papers
pre-clinical models
WHITE PAPER
A primer on the emerging biological understanding of Parkinson’s and its possible impact on the development of novel therapeutics and disease modelling.
DISCOVERY SERIES
Read the latest entry in our new series on the latest research on emerging targets in Parkinson’s Disease.
The Potential of BDNF/TrkB Pathway Modulation in Parkinson’s Disease
From data handling and analysis to transparent reporting protocols, EQIPD guidelines are helping to ensure researchers generate more robust and reliable data.
How researchers, clinicians, and companies are reading the current moment in Parkinson’s Research.
Unlike other quality systems, EQIPD has been designed to spur innovation in research without sacrificing rigor.
Patrick Howson on constantly improving Atuka’s quality system and the value of EQIPD.
WHAT OUR PARTNERS SAY
“Working with Atuka has been a highly satisfying experience! They exceeded our expectations in terms of quality, timeliness, and cost. Their knowledge and expertise in the Parkinson’s disease area were invaluable, helping us select and design in vivo models and obtain critical data to drive our projects toward success. We will definitely continue collaborating with Atuka as our program requires and recommend them to our peers without hesitation.”
– Kevin Fang, Chief Scientific Officer
Ignis Therapeutics
MEET THE ATUKA TEAM
"I've seen the suffering this disease causes," says Anna. "Being part of a team that contributes something to the research toward a cure is a huge motivator for me.”
Read More
After getting his start in Silicon Valley, Atuka's CFO Alan Stratton has spent his career finding new pathways to innovation.
Read More
Coming from a family of engineers in Tehran, Sahar Tamadon wanted to find her own niche.
Read More
Atuka's COO went from a budding orchestral double bassist to world leading researcher in Parkinson's disease.
Read MoreSERVICES & CAPABILITIES
Expanding the frontiers of research into neurodegenerative disorders
While our roots are in Parkinson’s research, Atuka has developed extensive preclinical experience developing therapies for numerous other indications—including cognitive disorders, ALS and other movement disorders such as dystonia and dyskinesia—across multiple modalities, such as biologics (including gene therapy) and small molecules.
Redefining innovation
Atuka is unique among contract research organizations. Not only do we provide our partners with industry-leading expertise in preclinical trial design and interpretation, but we are committed to ongoing scientific discovery in Parkinson’s disease and other disorders through an extensive internal research program, while actively contributing to and engaging with the scientific literature.
Our sites and facilities
Our partners benefit from globally-recognized scientists using advanced technologies at leading-edge research and lab facilities in Canada and China.
Atuka is a world expert in NHP research and has the capacity to conduct both small and large studies that use up to 150 macaques at our newly renovated, AAALAC-accredited facility in Suzhou, China. We are able to perform studies no other CRO can, while adhering to the highest standards of animal welfare.
With a depth of preclinical experience unparalleled in our field globally, Atuka has collaborated with over 90 organizations, including large pharmaceutical and biotech companies, charitable foundations, universities, and government agencies.
TALK TO OUR EXPERTS
Sign up to receive our quarterly newsletter featuring the latest developments in Parkinson’s disease research.